The Optimal Time for Initiating Probiotics for Preterm and Very-Low-Birth-Weight Infants: A 10-Year Experience in a

JeongHoon Park1,2, Jae Young Cho1,2, Jung Sook Yeom1,2,3

  • 1Department of Pediatrics, Gyeongsang National University Hospital, Jinju, Korea.

Insights

Initiating probiotic supplementation early, within seven days of birth, may significantly reduce adverse outcomes in preterm and very low birth weight infants. This early intervention is linked to better clinical results.

Area of Science:

  • Neonatal Medicine
  • Microbiome Research
  • Pediatric Nutrition

Background:

  • Probiotic supplementation timing in preterm infants is variable.
  • Optimal initiation strategies for probiotics in premature infants are not well-defined.
  • Early life microbial colonization is critical for infant development.

Purpose of the Study:

  • To determine the optimal timing for initiating probiotic supplementation in preterm or very low birth weight (VLBW) infants.
  • To investigate the association between early probiotic introduction and adverse neonatal outcomes.
  • To compare clinical outcomes between early and late probiotic administration.

Main Methods:

  • Retrospective review of medical records for preterm infants (<32 weeks GA) or VLBW infants (2011-2020).
  • Categorization into early introduction (EI) group (probiotics within 7 days) and late introduction (LI) group (probiotics after 7 days).
  • Statistical analysis of clinical characteristics and outcomes between EI and LI groups, including multivariate analysis.

Main Results:

  • A total of 370 infants were analyzed. The LI group had significantly lower gestational age and birth weight compared to the EI group.
  • Late probiotic introduction was independently associated with increased risks of late-onset sepsis (OR, 2.85), delayed full enteral nutrition (OR, 5.44), and extrauterine growth restriction (OR, 1.67).
  • Gestational age at birth and enteral nutrition start day were significant factors influencing late probiotic initiation.

Conclusions:

  • Early probiotic supplementation within the first week of life may be beneficial for preterm and VLBW infants.
  • Timely probiotic administration could mitigate risks of serious adverse neonatal outcomes.
  • Further research may confirm the benefits of early probiotic use in vulnerable infant populations.
Abstract

Related Concept Videos

Anatomy of the Intestines01:23

Anatomy of the Intestines

Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
72.7K
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
378
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
237